CD274 and neoplasm: Furthermore, beyond the most responsive tumor types (e.g., ultraviolet radiation–driven tumors), first-line anti-PD-L1 treatments have largely been advanced in combination with other agents (most commonly chemotherapy) given the modest response rates observed to anti-PD-(L)1 monotherapy in most tumor types (36).